Microscopic photo from National Cancer Institute

Sector group

Life sciences

HGF’s life sciences attorneys understand the challenges associated with commercially focused IP management and can advise on the pertinent issues, from invention conception through to patent term extension, to maximise the value of intellectual property.

Lady looking into test tube

As one of Europe’s largest groups of specialist life science attorneys, HGF has the wealth of technical and legal expertise to deliver truly global, commercially-focused strategies.

From protecting new research from Europe’s most prestigious universities, to high-profile oppositions for international healthcare companies on market-leading technologies, the team possesses in-depth legal experience. Particular technical expertise within the group covers the fields of food technology, microbiome for therapeutic purposes, cell and gene therapy, bioinformatics, cleantech, AgBio, immunobiology, gene editing technologies, personalised medicine, bioprocessing and anti-infectives.

In addition, our life sciences attorneys work closely with our IP lawyers in relation to life cycle agreements such as MTAs, R&D collaborations, companion diagnostics, IP licensing, clinical trials through to commercial manufacturing and supply, and litigation.

Latest updates

Paul Sanderson

We are sorry to announce that Paul Sanderson is leaving HGF on 30 September 2021. Paul joined HGF in February 2002 to establish HGF Law, becoming CEO of the wider …

Read article

IAM Strategy 300 2021

IAM Strategy 300 Global Leaders guide has been published and HGF is delighted to have 4 Partners listed. The guide draws from the worlds of private practice, consulting and other …

Read article

Decision of the EBoA regarding G1/21

Oral proceedings by videoconference can be enforced by the EPO during the pandemic On 16 July 2021 the EPO’s Enlarged Board of Appeal (EBoA) decided on referral G 1/21 regarding …

Read article

New appointments and changes to the leadership team at HGF as it continues to strengthen its position in the marketplace

We are pleased to announce that HGF has appointed a new CEO, Martyn Fish. Martyn was previously Head of HGF’s Law team and is a successful IP litigator. He has …

Read article

IAM Patent 1000 2021

The IAM Patent 1000 – the world’s leading patent professionals 2021 guide has now been published. HGF has 18 European attorneys listed. IAM Patent 1000 is a unique guide that …

Read article

G1/21 hearing at the EPO - July

G1/21 hearing continues on 2nd July 2021. Follow this page for updates from HGF Partner Douglas Drysdale and Patent Director Ellie Purnell, who will be reporting all the key moments …

Read article

EPO Enlarged Board of Appeal decision G4/19 - a European patent application can be refused by reason of the prohibition on double patenting

The European Patent Office today confirmed in Decision G4/19 of the Enlarged board of Appeal that a European patent application can be refused for ‘double patenting’.  Such a refusal can …

Read article

HGF ranked in the Financial Times special report 2021

HGF has been ranked in the Financial Times special report ‘Europe’s Leading Patent Law Firms’ published on the 17th June 2021. More than 10,000 patent attorneys working in patent law …

Read article